Article
IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas.
Neuro-oncology - 6 Apr 2023
van Opijnen Mark P, Tesileanu C Mircea S, Dirven Linda, van der Meer Pim B, Wijnenga Maarten M J, Vincent Arnaud J P E, Broekman Marike L D, Dubbink Hendrikus J, Kros Johan M, van Duinen Sjoerd G, Smits Marion, French Pim J, van den Bent Martin J, Taphoorn Martin J B, Koekkoek Johan A F
Abstract excerpt
BACKGROUND: IDH1/2 wildtype (IDHwt) glioma WHO grade 2 and 3 patients with pTERT mutation and/or EGFR amplification and/or + 7/-10 chromosome gain/loss have a similar overall survival time as IDHwt glioblastoma patients, and are both considered glioblastoma IDHwt according to the WHO 2021 classification. However, differences in seizure onset have been observed. This study aimed to compare the course of epilepsy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.